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The chemical and electrical microenvironment of neurons within the central nervous
system is protected and segregated from the circulation by the vascular blood–brain
barrier. This barrier operates on the level of endothelial cells and includes regulatory
crosstalk with neighboring pericytes, astrocytes, and neurons. Within this neurovascular
unit, the endothelial cells form a formidable, highly regulated barrier through the
presence of inter-endothelial tight junctions, the absence of fenestrations, and the
almost complete absence of fluid-phase transcytosis. The potent psychostimulant drug
methamphetamine transiently opens the vascular blood–brain barrier through either
or both the modulation of inter-endothelial junctions and the induction of fluid-phase
transcytosis. Direct action of methamphetamine on the vascular endothelium induces
acute opening of the blood-brain barrier. In addition, striatal effects of methamphetamine
and resultant neuroinflammatory signaling can indirectly lead to chronic dysfunction
of the blood-brain barrier. Breakdown of the blood-brain barrier may exacerbate the
neuronal damage that occurs during methamphetamine abuse. However, this process
also constitutes a rare example of agonist-induced breakdown of the blood-brain barrier
and the adjunctive use of methamphetamine may present an opportunity to enhance
delivery of chemotherapeutic agents to the underlying neural tissue.
Keywords: methamphetamine, blood-brain barrier, endothelial cell, neurovascular unit, pinocytosis, tight
junctions, neuroinflammation, CNS chemotherapy
Properties of the Blood Brain Barrier
The vasculature pervading the nervous system is exceptionally specialized and because of its
restrictive nature has been dubbed the blood brain barrier (BBB). The BBB controls the ionic
microenvironment for the central nervous system (CNS). It excludes neurotoxic plasma proteins
and yet enables cellular and molecular crosstalk between the periphery and the brain parenchyma
(Abbott et al., 2010). The importance of the BBB is best illustrated in disease when it is often
compromised. Hallmarks of a dysfunctional BBB include unchecked passage of leukocytes, ions,
plasma proteins and water, with progression to oedema and irrevocable CNS damage. This
contributes to the pathology of classical BBB breakdown such as stroke or trauma (Lo et al., 2003)
but also neuroinflammatory diseases such as multiple sclerosis (Alvarez et al., 2011; Argaw et al.,
2012). More recently, disorders previously considered exclusively neurological in their etiology,
such as Parkinson’s and Alzheimer’s disease or amyotrophic lateral sclerosis, have also been found
Abbreviations: BBB, blood-brain barrier; CNS, central nervous system; EC, endothelial cell; TJ, tight junction; CLDN,
claudin; PV-1, plasmalemmal vesicle associated protein-1; ABC, ATP-binding cassette (transporters); MMP, matrix
metalloproteinases; METH, methamphetamine.
Turowski and Kenny Methamphetamine at the blood-brain barrier
to be accompanied or even caused by significant BBB dysfunction
(Drozdzik et al., 2003; Jeynes and Provias, 2011). From a
pharmacological point of view, the BBB presents a formidable
impediment to efficient delivery of therapeutic agents into the
brain. Therefore, much BBB research focuses on finding ways to
breach the barrier for therapeutic purposes (Patel et al., 2009).
Cells Contributing to the BBB
The properties of the BBB are defined by the neurovascular
unit, which is the functional association of cerebrovascular
endothelial cells (ECs) with neurons and non-neuronal cells
including pericytes, astrocytes, perivascular macrophages, and
microglia (Daneman, 2012). The actual barrier operates mostly at
the level of the microvascular EC, which display a sophisticated
tight junction (TJ) network, a lack of fenestrae and low levels of
fluid phase transcytosis (pinocytosis), all of which restricts the
passage of molecules and cells. The luminal face of the BBB ECs is
covered by a glycocalyx, a non-selective first line filtration barrier
(Van Teeffelen et al., 2007).
On the abluminal side cerebral ECs interact with surrounding
pericytes with which they share a basement membrane. Pericyte
coverage at the BBB and blood-retinal barrier is the highest
of all vascular beds, with EC to pericyte ratios typically
ranging between 1:1 and 3:1 (Armulik et al., 2011). Pericytes
are essential for BBB formation during development and also
strongly influence its mature properties and function during
health and disease. For instance, pericytes suppress EC functions
that normally facilitate transcellular permeability and leukocyte
infiltration in the periphery (Armulik et al., 2010; Daneman et al.,
2010). Dysfunctional pericyte-endothelial interactions appear to
drive the pathogenesis of neurodegenerative diseases such as
Alzheimer’s disease (Montagne et al., 2015).
Astrocytes ensheath CNS blood vessels and, either directly
or via the parenchymal basement membrane, regulate neuronal
function and coordinate multitudinous signals from neurons,
the BBB and their microenvironment during such instances as
neurovascular coupling linking neural activity to blood flow
(Petzold and Murthy, 2011). Astrocytes also strongly influence
both BBB TJs and transport properties (Abbott et al., 2010).
CNS immune cells include microglia, which are highly
ramified, phagocytic cells found throughout the CNS. They
contribute to innate and adaptive immune responses and
neuronal homeostasis (Daneman, 2012). Perivascular BBB
macrophages reside between the basal lamina and astrocytic foot
processes, where they are involved in first line CNS immune
surveillance and antigen presentation (Daneman, 2012). Their
activation affects the BBBwith an increased secretion of cytokines
contributing to increased permeability and leukocyte infiltration
(Denieffe et al., 2013).
Molecular Characteristics of the Vascular
Barrier of the CNS
TJs are a dynamic protein complex connecting adjoining
epithelial and ECs (Steed et al., 2010). In addition, by
separating luminal from abluminal cellular surfaces, TJs, and
to a lesser degree adherens junctions (Dejana and Orsenigo,
2013), are responsible for regulating the passage of solutes
and cells through the paracellular space, for the establishment
and maintenance of apico-basal polarity and for cell-cell-
contact mediated intracellular signaling. TJs are composed of
transmembrane proteins which regulate cell-cell interactions, the
lateral organization of junction strands as well as associations
with cytoplasmic TJ proteins. Claudins (CLDNs) are by far
the most dominant transmembrane protein found in BBB TJs.
They constitute a large family of proteins, which form the
structural fabric of TJs through homophilic and heterophilic,
cis and trans interactions. Depending on the isoform, claudins
can be pore or fence forming. At least three CLDNs (3, 5,
and 12) have been identified in BBB ECs. CLDN5 contributes
to BBB function in that it regulates paracellular transport of
small (<800 dalton) blood solutes (Nitta et al., 2003). Occludin
is another transmembrane protein present in all epithelial and
endothelial TJs, which regulates certain aspects of paracellular
diffusion and TJ organization in vitro (Steed et al., 2010). Other
transmembrane proteins of BBB TJs include junctional adhesion
proteins and tricellulin. Cytoplasmic TJ proteins, such as zona
occludens proteins ZO-1, ZO-2, and ZO-3, cingulin, binding
partitioning defective proteins PAR-3 and PAR-6, MAGI and
MUPP1 and AF-6, densely pack the space beneath the cell
membrane and dynamically link the integral membrane proteins
to the cytoskeleton and a multitude of intracellular signaling
proteins. However, many of the described molecular features of
TJs are not exclusive to the BBB and cannot fully account for the
exceptional solute and electrical impermeability of the cerebral
vasculature.
The healthy BBB endothelium lacks fenestrae and exhibits
very low levels of transcytosis (Daneman, 2012). This might be
due to the lack of a glycoprotein called plasmalemmal vesicle
associated protein-1 (PLVAP or PV-1). PV-1 was first identified
as a caveolar protein and thus with a role in vesicular trafficking.
Subsequently it was identified as a key element in the formation of
fenestrae diaphragms. At the healthy BBB, pericytes suppress PV-
1’s expression, which conversely is enhanced during pathological
BBB breakdown (Shue et al., 2008; Daneman, 2012). A pericyte-
deficient BBB features increased macromolecular permeability
with increased cytoplasmic vesicles but with intact polarization
and a continued lack of fenestrae (Armulik et al., 2010; Daneman
et al., 2010).
In addition to restricting unwanted passage of cells and
solutes, ECs have to allow regulated nutrient and immune cell
entry into the CNS and ensure removal of toxic substances
and waste. This is achieved by five different mechanisms:
passive diffusion, ATP-binding cassette (ABC) transporters,
solute carriers, transcytosis, and transendothelial migration of
leukocytes (Saunders et al., 2013). BBB ECs display exceptional
apico-basal polarization with respect to the expression profile of
many of these transport systems, enabling preferential transport
to or from brain. Lipid soluble, non-polar molecules can diffuse
across the BBB unrestricted, as do oxygen and carbon dioxide,
moving along concentration gradients. ABC transporters, such
as P-glycoprotein and multidrug resistance-associated proteins,
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function as active eﬄux pumps and transport lipid soluble
compounds out of the CNS. In turn, many of the essential polar
nutrients, such as glucose and amino acids, are transported into
the CNS by specific solute carriers. Larger molecular weight
proteins and peptides generally enter the CNS via endothelial
transcytosis. Whilst leukocytes appear to migrate through both
the healthy and diseased vascular BBB, diapedesis appears to
be primarily transcellular at the intact BBB (Engelhardt and
Wolburg, 2004; Daneman, 2012).
Modulation of the BBB under
Pathophysiological Conditions
On the one hand a pathologically weakened BBB could provide a
better immune response, but on the other hand have profound
adverse effects on the CNS, inciting neuronal damage and
degeneration. A disrupted BBB is characterized by aberrations
in both paracellular and transcellular pathways (Stamatovic
et al., 2008). Faulty paracellular transport develops following
changes in the phosphorylation and adhesive properties of TJ
and adherens junction complexes, resulting in altered junctional
protein interactions, localization, or even down-regulation.
Concomitant reorganization of the actin cytoskeleton also
contributes to permeability, with contractile forces thought to
render the paracellular space more compliant to modification
(Stamatovic et al., 2008). Matrix metalloproteinases (MMPs),
most notably MMP9, are activated by reactive oxygen species,
vascular endothelial growth factor and inflammatory cytokines in
many CNS pathologies (Daneman, 2012). MMP activation leads
to the degradation of EC basement membrane and enhanced
phosphorylation and cleavage of TJ proteins, with subsequent
degradation of the interendothelial junctions. The development
of faulty transcellular transport has been less extensively studied,
however early brain oedema, and increased expression of
caveolin-1, has been found to precede disruptions to TJ protein
expression (Nag et al., 2007). Potential mediators of this early
event in BBB dysfunction include vascular endothelial growth
factor, which induces pinocytic vesicles in blood-retinal barrier
(Hofman et al., 2000) and blood tumor barrier endothelium
in conjunction with increased expression of caveolin-1 and −2
(Zhao et al., 2011). Bradykinin also induces transcellular
transport within blood tumor barrier endotheliumwith increased
expression of caveolin-1 and−2 (Liu et al., 2010).
Methamphetamine-induced BBB
Dysfunction
Methamphetamine (METH) is a highly addictive CNS stimulant
with demonstrated neurotoxicity. Long-term damage to
monoaminergic nerve terminals is caused by excitotoxicity,
mitochondrial dysfunction, and increased production of
reactive oxygen and nitrogen species (Quinton and Yamamoto,
2006). METH readily crosses the BBB due to its small size
and lipophilicity. It is also a substrate for the organic cation
transporters OCT3 and OCTN2 (Wu et al., 1998a,b), with
the latter undisputedly expressed in BBB ECs (Friedrich et al.,
2003). METH rapidly accumulates in the brain parenchyma
of rodents (Martins et al., 2011), and this suggests that, unlike
other lipophilic drugs, METH evades BBB eﬄux pump activity.
Moreover, METH exposure alters the permeability of the BBB
and this is likely to exacerbate its neurotoxicity.
In reviewing data relating to METH-induced BBB opening
we would like to begin with our observation that such meta-
analysis is complicated due to the highly varied protocols
used to mimic METH intoxication, both in vitro and in vivo.
Most studies do not report detailed kinetic or concentration
dependent methods. Furthermore, literature on METH-induced
BBB breakdown is replete with studies reporting the effects of
METH at concentrations that are hugely in excess of those
found in typical drug abuse, and are in fact associated with
lethality (Takayasu et al., 1995). Very high concentrations of
METH in preclinical experiments in rodents unsurprisingly lead
to neurotoxic stress, hyperthermia and death, and it is likely that
BBB breakdown in these instances is a consequence of METH-
induced brain death. In this review we focus on studies that have
employedMETH concentrations that are likely to reflect relevant
(but not lethal) abuse scenarios.
A number of studies have shown significant breakdown of the
BBB in rodents in response to METH administration (Table 1).
However, few of the studies controlled the plasma concentrations
of METH during the observation period.
Martins et al. (2011) find that a single 30mg/kg METH
i.p. injection in mice leads to a peak plasma concentration of
ca. 30µM after about 1 h. In human subjects typical METH
abuse leads to plasma concentrations in the mid µM range
with concentrations above 30µM considered lethal (Cook et al.,
1992; Melega et al., 2007). Acute administration of METH
at such concentrations in rodents consistently leads to BBB
breakdown, visualized by measuring plasma protein (albumin or
IgG) accumulation in the parenchyma. Significant accumulation
of these proteins was generally observed after several hours
(Table 1). Protocols mimicking chronic abuse fail to demonstrate
significant BBB dysfunctions but transient BBB opening may
have been missed due to the experimental paradigm used
(Kousik et al., 2011). METH induces some BBB breakdown
across the entire CNS but studies have noted a certain tropism,
with protein extravasation significantly more prominent in
the hippocampus (Bowyer et al., 2008; Sharma and Kiyatkin,
2009; Martins et al., 2011). These data are in line with others
indicating that the BBB of the hippocampus is particularly
sensitive (Terrando et al., 2014; Montagne et al., 2015). In vitro
studies using primary or immortalized monocultures of brain
microvascular ECs also found enhanced permeability in the
presence of METH, albeit many studies employed concentrations
of METH greater than 50µM (Mahajan et al., 2008; Ramirez
et al., 2009; Martins et al., 2013). The simplest paradigm arising
from in vivo and in vitro data suggests that METH induces
endothelial permeability, leading to a transient opening of the
BBB, which then contributes to the neurotoxic features of METH
(see Figure 1). However, this simplemodel should be treated with
caution. Careful comparison of the in vitro and in vivo datasets
indicates that barrier dysfunction occurs with significantly
different kinetics following METH exposure. In vitro, using
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TABLE 1 | Studies investigating the effect of METH on BBB integrity.
Effective METH dosage causing
barrier breakdown
Time scale of observed changes Experimental model References
In vivo studies 9mg/kg >1 h Rat Kiyatkin et al., 2007
40mg/kg or daily 10mg/kg 1.5 h to 3 days Mouse Bowyer et al., 2008
Repeated dose of 1.5–10mg/kg 9 days Mouse Ramirez et al., 2009
9mg/kg >1 h Rat Sharma and Kiyatkin, 2009
4× 10mg/kg 3 days Mouse Kuroda et al., 2010
3mg/kg or 9mg/kg (acute);
2–3mg/kg self-adminstered (chronic)
24 h (acute); 10 days (chronic) Rat Kousik et al., 2011
30mg/kg 24 h Mouse Martins et al., 2011
3× 4mg/kg over 9 h 3–24 h Mouse ElAli et al., 2012
10mg/kg 1 h Mouse Park et al., 2013
3× 4mg/kg over 9 h 10 h Mouse Urrutia et al., 2013
In vitro studies 10–50 nM 24h Astrocyte-EC co-culture (human) Mahajan et al., 2008
50µM 2h Primary EC (human) Ramirez et al., 2009
>10µM ≥1 h hCMEC/D3 cell line (human) Park et al., 2012
1µM <1 h primary EC (rat) Martins et al., 2013
10µM 1h hCMEC/D3 cell line (human) Park et al., 2013
endothelial monocultures, METH induces permeability within
less than 1 h. In contrast, in vivo, METH effects on the BBB
generally take more than an hour to develop and are often
observed to persist chronically for many hours/days. This could
be due to a lack of sensitivity in detecting leakage at the BBB
through extravasated plasma proteins. More direct and acute
measurements of BBB breakdown could be employed to exclude
this possibility (Hudson et al., 2014). Nevertheless, the reported
kinetic discrepancies indicate that METH affects BBB integrity in
at least two ways (Figure 1). Firstly, it acts acutely and directly on
brain microvascular ECs, inducing permeability within minutes.
Here the effective concentration range of METH is relatively
narrow (Martins et al., 2013). Secondly, METH induces BBB
breakdown in a delayed and possibly chronic, inflammatory
fashion, as a consequence of neuronal damage, glia activation and
hyperthermia (O’Shea et al., 2014). Enhanced BBB sensitivity to
METH of FosB null mice supports the existence of this second,
indirect pathway (Kuroda et al., 2010).
The strong effects of low micromolar, or even submicromolar,
concentrations ofMETH inmonocultures of brainmicrovascular
ECs point toward the existence of a direct binding protein for
METH (Mahajan et al., 2008; Ramirez et al., 2009; Martins
et al., 2013). METH can bind and affect the activity of a
wide variety of proteins, most of which are expressed in
neurons and nerve terminals1. METH stimulation of the trace
amine-associated receptor 1, a G-protein coupled receptor, is
considered of particular importance (Bunzow et al., 2001).
It is yet unclear whether this receptor, or any of the other
relevant targets of METH, is expressed in brain microvascular
ECs but preliminary data suggests that this might be the
case2.
1http://www.drugbank.ca/drugs/DB01577#targets
2http://www.proteinatlas.org/ENSG00000146399-TAAR1/tissue/cerebral+cortex
The responses of brain microvascular ECs to METH are
varied. Reduction of TJ proteins, in particular of occludin but
also CLDN5, has been observed in rodents (Martins et al., 2011)
and in cultures of brain microvascular ECs (Ramirez et al.,
2009; Park et al., 2012). Importantly, the effect on the junctions
usually requires high concentrations of METH and takes hours
to become noticeable. TJ protein downregulation is likely to be
a consequence of oxidative stress, with antioxidants relieving
some symptoms of METH-induced BBB dysfunction (Park et al.,
2012, 2013; Urrutia et al., 2013). ARP2/3-mediated endocytosis
also appears to play a role (Park et al., 2013). Increased MMP
activity in response toMETH contributes to BBB dysfunction and
TJ downregulation, with significant attenuation observed in the
presence of MMP inhibitors (Martins et al., 2011; Urrutia et al.,
2013). With neuroinflammation and associated cytokine release
being another hallmark of METH intoxication (Goncalves et al.,
2008; O’Shea et al., 2014), it is likely that MMPs are derived by
glial cells (Conant et al., 2004) or invading leukocytes, just as in
many other instances of pathological BBB breakdown (Daneman,
2012).
Using a primary EC model highly predictive of the intact
BBB (Hudson et al., 2014), our group has found that
moderate concentrations of METH, corresponding to plasma
concentrations in typical drug abusers, lead to rapid endothelial
leakage through a fluid phase, i.e., vesicular pathway, with TJs
left intact (Martins et al., 2013). This data is in agreement
with a paradigm of enhanced vesicular transport preceding TJ
breakdown at the BBB in certain pathophysiological conditions
(see above).METH-induced fluid phase transcytosis is dependent
on endothelial nitric oxide synthase activity but other key
mechanistic questions, e.g., pertaining to the potential regulation
by PV-1 or by adjacent pericytes (and other components of the
neurovascular unit which might regulate vesicular transport at
the BBB) remain. It also needs to be established if both para- and
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FIGURE 1 | METH action in the CNS and proposed pathways of BBB
opening. Current literature supports a model, where METH affects the
transport properties of BBB ECs directly (1◦) and indirectly (2◦) through
inflammatory signaling following glial activation, aminergic nerve (ANE) damage
and hyperthermia. The indirect pathway is likely to involve microglia (MG)
activation and transmigrating leukocytes (LC). Current experimental evidence
suggests that the opening of the BBB occurs on the level of TJs and
fluid-phase vesicular transport. AE, astrocyte endfoot; PC, pericyte.
transcellular BBB permeability are induced by METH and if so
under which conditions, especially since, as seen with leukocyte
migration, the route may depend on the respective tightness of
the experimental model used (Ransohoff and Engelhardt, 2012).
Exploiting Meth for Delivering
Therapeutics to the CNS
The observation that BBB breakdown is transient and thus
resembles an agonist-driven (or therapeutic) opening of the
BBB, suggests that METH and related compounds could be
used to enhance the transport of other drugs to the CNS.
Indeed, this is an idea proposed as early as 2007 (Kast, 2007)
and, given that METH is FDA approved, has been picked up
repeatedly since (Focosi and Kast, 2010; Sardi, 2011; Capeloa
et al., 2014). However, preclinical or clinical data in support of
such a therapeutic strategy have not yet been reported. Before
METH is trialed as an adjuvant to CNS chemotherapy, a number
of aspects of METH-induced pathology should be considered.
For instance, is there a need to harness the neurostimulatory or
neurotoxic action of METH? How does METH affect diseased
CNS cells, e.g., glioblastoma (Capeloa et al., 2014)? Will the
apparent tropism of METH restrict its effectiveness to parts of
the CNS such as the hippocampus?
Concluding Remarks
Research into the effects of METH on the BBB should be
considered topical and highly relevant, and not just with regard to
understanding METH abuse and its neurological consequences.
METH affects barrier function of BBB ECs directly but also
induces a response, which is reminiscent of neuroinflammation,
in that it involves glial activation, cytokine, and MMP release as
well as oxidative stress. Mechanistic insights into METH action
are likely to enhance our understanding of the BBB, particularly
the molecular and cellular mechanisms of its pathophysiological
regulation, as well as reveal vital insight into the specificity of BBB
eﬄux pumps for monoamines. Finally, research into METHmay
even facilitate our reach toward disease targets currently hidden
behind the BBB.
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